Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. - Wikidata - wikimedia - TriplyDB

Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients.

Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients.

http://www.wikidata.org/entity/Q34575453

about

Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer.UGT genotyping in belinostat dosing Genetic factors affecting drug disposition in Asian cancer patients.Glucuronides in the gut: Sugar-driven symbioses between microbe and host.Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma.Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma.Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia.Combined use of irinotecan with histone deacetylase inhibitor belinostat could cause severe toxicity by inhibiting SN-38 glucuronidation via UGT1A1.Pharmacogenomics and histone deacetylase inhibitors.In vitro characterization of belinostat glucuronidation: demonstration of both UGT1A1 and UGT2B7 as the main contributing isozymes.Metabolism of the anthelmintic drug niclosamide by cytochrome P450 enzymes and UDP-glucuronosyltransferases: metabolite elucidation and main contributions from CYP1A2 and UGT1A1.UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation.

P2860

Q33425469-6351AD18-E5D3-4A6E-A6BA-D37BAAE98904 Q33429235-0697C905-9FFB-4F31-AE89-710A1C07BEFF Q34501025-FDF0B513-90BC-46A2-BEAB-6B9E8A37EB36 Q36340552-0F21864F-401F-4266-B6C5-E4C6FAB8CFD3 Q37579991-37832DC5-5E0E-4E43-8CD4-2A0AD42BF5E9 Q38515832-BFCEF35B-85C9-443E-8E23-3E65590A2881 Q38740254-15C348D5-7495-4DF4-B36C-3905ED0E9ED2 Q38981028-DAC35322-2052-4BE4-A09C-8C129751CAE2 Q38987332-3AEF9BEC-7A7C-4CEF-A0E9-13896D46EA7D Q39765064-123AA79E-B412-4DBB-9D2A-D82A080A52E1 Q46715656-7DD70DBB-DD4A-4549-931A-536D6D53CF8D Q50546142-3DE94176-1D4D-4D3D-B384-295CC3760FF8

P2860

Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients.

http://www.wikidata.org/entity/Q34575453

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Glucuronidation by UGT1A1 is t ...... stat in liver cancer patients.

@ast

Glucuronidation by UGT1A1 is t ...... stat in liver cancer patients.

@en

Glucuronidation by UGT1A1 is t ...... stat in liver cancer patients.

@nl

type

label

Glucuronidation by UGT1A1 is t ...... stat in liver cancer patients.

@ast

Glucuronidation by UGT1A1 is t ...... stat in liver cancer patients.

@en

Glucuronidation by UGT1A1 is t ...... stat in liver cancer patients.

@nl

prefLabel

Glucuronidation by UGT1A1 is t ...... stat in liver cancer patients.

@ast

Glucuronidation by UGT1A1 is t ...... stat in liver cancer patients.

@en

Glucuronidation by UGT1A1 is t ...... stat in liver cancer patients.

@nl

P1433

Q34575453-C2D038E5-E0E6-4EB9-8A86-B2EFB7D7C966

P1476

Q34575453-50C9B9BF-A70D-4EE6-8F39-EE386DDCC89C

P2093

Q34575453-20181880-36A9-4725-A8D1-5123EBCD8218

Q34575453-354FF868-C7B6-4C41-B6A8-39AA036F1374

Q34575453-3A068B16-61EF-4E25-AD15-7B0E77042637

Q34575453-3C9BC72A-2885-4404-872A-5D7840D6DC0E

Q34575453-52E943D3-E175-40AD-BC6F-BC0E01A794A5

Q34575453-7A6B09CD-6352-447D-869B-E44E3DEA5A49

Q34575453-850CAE40-B916-4F28-9218-E63AD1E8E400

Q34575453-91BBBD19-E3D9-4D00-BFC7-15A4E740FFC9

Q34575453-A7600819-7E12-4704-A9BA-C0AEF6E7C55F

Q34575453-B8B12B57-2198-405D-8904-E2752CB5C028

P2860

Q34575453-06809F5A-C0FD-4588-9605-965871F6289A

Q34575453-0983F58A-F412-49C2-8677-F46B7C759B9C

Q34575453-0BFC4760-284A-4908-A8E5-414ED7399970

Q34575453-0C870F77-E29D-4A8C-8BB5-E7223F7EACAE

Q34575453-1C338AC5-B4D1-4037-9CBF-DFAA4DAC204B

Q34575453-230FB1C7-52A6-4767-B2EE-765B4708BB6B

Q34575453-23E217AE-7DD1-413C-BC76-8F6B5DFF3A53

Q34575453-23EDBC3C-EB03-4460-AC3B-7DF985C16CC4

Q34575453-29BE66D2-6396-47E0-9230-E305E28CA403

Q34575453-54959A76-C55A-487F-9A51-5153A58EF2F5

P304

Q34575453-6ACE82BB-739A-4C11-8DFE-95CB7DD3DF70

P31

Q34575453-2C1927E6-FEB7-43A6-8D35-B9CD732C2B5C

P356

Q34575453-D73A7EF9-4498-4077-BF2E-BB363819800D

P407

Q34575453-8A0B0BFE-93CB-4FDE-A82B-477E1C9CB1B1

P433

Q34575453-F22C6A93-676F-404F-A0A9-6DA8A33021C0

P478

Q34575453-778D0832-F84A-49A3-B240-27AFE47F52BC

P50

Q34575453-47BF5834-5621-40E0-BFB9-06C489D68148

Q34575453-E0E50BD5-EE56-47D8-A73C-16B18032FDFD

P577

Q34575453-043C68B9-21A8-4108-847C-88AC9B2469B0

P5875

Q34575453-9CBCD027-55F7-4837-882B-399D98CDF511

P698

Q34575453-1448C6E6-ADDC-4A18-A5F9-7B9E08539A33

P921

Q34575453-7303815F-2076-4306-9B51-DC7B6F175894

P932

Q34575453-F03E7776-4401-4946-B8DD-9B675E31FEE1

P356

JOURNAL.PONE.0054522

P1433

P1476

Glucuronidation by UGT1A1 is t ...... stat in liver cancer patients.

@en

P2093

Andrea Li-Ann Wong

http://www.w3.org/2001/XMLSchema#string

Anthony Chan

http://www.w3.org/2001/XMLSchema#string

Boon-Cher Goh

http://www.w3.org/2001/XMLSchema#string

How-Sung Lee

http://www.w3.org/2001/XMLSchema#string

Jacqueline Ramírez

http://www.w3.org/2001/XMLSchema#string

Jie-Ying Amelia Lau

http://www.w3.org/2001/XMLSchema#string

Ling-Zhi Wang

http://www.w3.org/2001/XMLSchema#string

Mei-Yi Michelle Chan

http://www.w3.org/2001/XMLSchema#string

Paul C Ho

http://www.w3.org/2001/XMLSchema#string

Robert Lim

http://www.w3.org/2001/XMLSchema#string

P2860

Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan

Expression of the UDP-glucuronosyltransferase 1A locus in human colon. Identification and characterization of the novel extrahepatic UGT1A8

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma.

Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors.

The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome.

Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors.

Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.

P304

e54522

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0054522

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-01-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235402830

http://www.w3.org/2001/XMLSchema#string

P698

23382909

http://www.w3.org/2001/XMLSchema#string

P921

P932

3559838

http://www.w3.org/2001/XMLSchema#string